Indian drug maker  Lupin  said that it has entered into a License, Supply and Technology Sharing agreement with Axantia Holding , a leading pharmaceutical company operating through its subsidiaries PharmaInternational Company and Med CityPharmaceutical Industries, for the Middle East and North African region. Under the terms of agreement, Axantia will register, distribute and market biosimilar Pegfilgrastim Drug products in certain territories including Saudi Arabia, certain GCC countries, Jordan, Lebanon, Iraq, Sudan, Libya and Algeria.